Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 56

1.

Changes in risk behaviours during and following treatment for hepatitis C virus infection among people who inject drugs: The ACTIVATE study.

Midgard H, Hajarizadeh B, Cunningham EB, Conway B, Backmund M, Bruggmann P, Bruneau J, Bourgeois S, Dunlop A, Foster GR, Hellard M, Robaeys G, Thurnheer MC, Weltman M, Amin J, Marks PS, Quiene S, Dore GJ, Dalgard O, Grebely J; ACTIVATE Study Group.

Int J Drug Policy. 2017 Jun 17. pii: S0955-3959(17)30144-5. doi: 10.1016/j.drugpo.2017.05.040. [Epub ahead of print]

PMID:
28633998
2.

Efficacy of response-guided directly observed pegylated interferon and self-administered ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study.

Grebely J, Dalgard O, Cunningham EB, Hajarizadeh B, Foster GR, Bruggmann P, Conway B, Backmund M, Robaeys G, Swan T, Amin J, Marks PS, Quiene S, Applegate TL, Weltman M, Shaw D, Dunlop A, Hellard M, Bruneau J, Midgard H, Bourgeois S, Staehelin C, Dore GJ; ACTIVATE Study Group.

Int J Drug Policy. 2017 Jun 14. pii: S0955-3959(17)30124-X. doi: 10.1016/j.drugpo.2017.05.020. [Epub ahead of print]

PMID:
28624134
3.

Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: the ACTIVATE study.

Cunningham EB, Hajarizadeh B, Dalgard O, Amin J, Hellard M, Foster GR, Bruggmann P, Conway B, Backmund M, Robaeys G, Swan T, Marks PS, Quiene S, Applegate TL, Weltman M, Shaw D, Dunlop A, Bruneau J, Midgard H, Bourgeois S, Thurnheer MC, Dore GJ, Grebely J; ACTIVATE Study Group.

BMC Infect Dis. 2017 Jun 13;17(1):420. doi: 10.1186/s12879-017-2517-3.

4.

Hepatitis C virus core antigen: A simplified treatment monitoring tool, including for post-treatment relapse.

Lamoury FMJ, Soker A, Martinez D, Hajarizadeh B, Cunningham EB, Cunningham P, Bruggmann P, Foster GR, Dalgard O, Backmund M, Conway B, Robaeys G, Swan T, Cloherty G, Marks P, Grebely J, Dore GJ, Applegate TL.

J Clin Virol. 2017 Jul;92:32-38. doi: 10.1016/j.jcv.2017.05.007. Epub 2017 May 11.

5.

Evaluation of the Xpert HCV Viral Load point-of-care assay from venepuncture-collected and finger-stick capillary whole-blood samples: a cohort study.

Grebely J, Lamoury FMJ, Hajarizadeh B, Mowat Y, Marshall AD, Bajis S, Marks P, Amin J, Smith J, Edwards M, Gorton C, Ezard N, Persing D, Kleman M, Cunningham P, Catlett B, Dore GJ, Applegate TL; LiveRLife Study Group.

Lancet Gastroenterol Hepatol. 2017 Jul;2(7):514-520. doi: 10.1016/S2468-1253(17)30075-4. Epub 2017 Apr 22.

PMID:
28442271
6.

HCV Cure and Reinfection Among People With HIV/HCV Coinfection and People Who Inject Drugs.

Martinello M, Hajarizadeh B, Grebely J, Dore GJ, Matthews GV.

Curr HIV/AIDS Rep. 2017 Jun;14(3):110-121. doi: 10.1007/s11904-017-0358-8. Review.

PMID:
28432579
7.

Hepatitis C treatment as prevention: evidence, feasibility, and challenges.

Hajarizadeh B, Grebely J, Martinello M, Matthews GV, Lloyd AR, Dore GJ.

Lancet Gastroenterol Hepatol. 2016 Dec;1(4):317-327. doi: 10.1016/S2468-1253(16)30075-9. Epub 2016 Nov 10. Review.

PMID:
28404202
8.

Ongoing incident hepatitis C virus infection among people with a history of injecting drug use in an Australian prison setting, 2005-2014: The HITS-p study.

Cunningham EB, Hajarizadeh B, Bretana NA, Amin J, Betz-Stablein B, Dore GJ, Luciani F, Teutsch S, Dolan K, Lloyd AR, Grebely J; HITS-p investigators.

J Viral Hepat. 2017 Mar 3. doi: 10.1111/jvh.12701. [Epub ahead of print]

PMID:
28256027
9.

Recommendations for the Clinical Management of Hepatitis C in Iran: A Consensus-Based National Guideline.

Alavian SM, Hajarizadeh B, Bagheri Lankarani K, Sharafi H, Ebrahimi Daryani N, Merat S, Mohraz M, Mardani M, Fattahi MR, Poustchi H, Nikbin M, Nabavi M, Adibi P, Ziaee M, Behnava B, Rezaee-Zavareh MS, Colombo M, Massoumi H, Bizri AR, Eghtesad B, Amiri M, Namvar A, Hesamizadeh K, Malekzadeh R.

Hepat Mon. 2016 Aug 13;16(8):e40959. eCollection 2016 Aug. Review.

10.

Higher incidence of HCV in females compared to males who inject drugs: A systematic review and meta-analysis.

Esmaeili A, Mirzazadeh A, Carter GM, Esmaeili A, Hajarizadeh B, Sacks HS, Page KA.

J Viral Hepat. 2017 Feb;24(2):117-127. doi: 10.1111/jvh.12628. Epub 2016 Oct 28.

PMID:
27790803
11.

Time to decompensated cirrhosis and hepatocellular carcinoma after an HBV or HCV notification: A population-based study.

Alavi M, Law MG, Grebely J, Amin J, Hajarizadeh B, George J, Dore GJ.

J Hepatol. 2016 Nov;65(5):879-887. doi: 10.1016/j.jhep.2016.06.025. Epub 2016 Jul 8.

PMID:
27401548
12.

Liver Disease Burden of Hepatitis C Virus Infection in Iran and the Potential Impact of Various Treatment Strategies on the Disease Burden.

Hajarizadeh B, Razavi-Shearer D, Merat S, Alavian SM, Malekzadeh R, Razavi H.

Hepat Mon. 2016 Jun 14;16(7):e37234. doi: 10.5812/hepatmon.37234. eCollection 2016 Jul.

13.

Hepatitis B-Related Concerns and Anxieties Among People With Chronic Hepatitis B in Australia.

Hajarizadeh B, Richmond J, Ngo N, Lucke J, Wallace J.

Hepat Mon. 2016 May 21;16(6):e35566. doi: 10.5812/hepatmon.35566. eCollection 2016 Jun.

14.

Trends in hepatocellular carcinoma among people with HBV or HCV notification in Australia (2000-2014).

Waziry R, Grebely J, Amin J, Alavi M, Hajarizadeh B, George J, Matthews GV, Law M, Dore GJ.

J Hepatol. 2016 Dec;65(6):1086-1093. doi: 10.1016/j.jhep.2016.08.010. Epub 2016 Aug 26.

PMID:
27569777
15.

HIV infection is associated with higher levels of monocyte chemoattractant protein-1 and eotaxin among people with recent hepatitis C virus infection.

Lamoury FM, Hajarizadeh B, Keoshkerian E, Feld JJ, Amin J, Teutsch S, Matthews GV, Hellard M, Dore GJ, Lloyd AR, Applegate TL, Grebely J; ATAHC Study Group.

BMC Infect Dis. 2016 Jun 1;16:241. doi: 10.1186/s12879-016-1567-2.

16.

Maximum levels of hepatitis C virus lipoviral particles are associated with early and persistent infection.

Sheridan DA, Hajarizadeh B, Fenwick FI, Matthews GV, Applegate T, Douglas M, Neely D, Askew B, Dore GJ, Lloyd AR, George J, Bassendine MF, Grebely J.

Liver Int. 2016 Dec;36(12):1774-1782. doi: 10.1111/liv.13176. Epub 2016 Jul 5.

PMID:
27224844
17.

Chronic hepatitis C burden and care cascade in Australia in the era of interferon-based treatment.

Hajarizadeh B, Grebely J, McManus H, Estes C, Razavi H, Gray RT, Alavi M, Amin J, McGregor S, Sievert W, Thompson A, Dore GJ.

J Gastroenterol Hepatol. 2017 Jan;32(1):229-236. doi: 10.1111/jgh.13453.

PMID:
27197716
18.

Alanine aminotransferase, HCV RNA levels and pro-inflammatory and pro-fibrogenic cytokines/chemokines during acute hepatitis C virus infection.

Hajarizadeh B, Lamoury FM, Feld JJ, Amin J, Keoshkerian E, Matthews GV, Hellard M, Dore GJ, Lloyd AR, Grebely J, Applegate TL; ATAHC Study Group.

Virol J. 2016 Feb 24;13:32. doi: 10.1186/s12985-016-0482-x.

19.

HIV infection and hepatitis C virus genotype 1a are associated with phylogenetic clustering among people with recently acquired hepatitis C virus infection.

Bartlett SR, Jacka B, Bull RA, Luciani F, Matthews GV, Lamoury FM, Hellard ME, Hajarizadeh B, Teutsch S, White B, Maher L, Dore GJ, Lloyd AR, Grebely J, Applegate TL.

Infect Genet Evol. 2016 Jan;37:252-8. doi: 10.1016/j.meegid.2015.11.028. Epub 2015 Nov 26.

20.

Strategies to manage hepatitis C virus infection disease burden - volume 3.

Alfaleh FZ, Nugrahini N, Matičič M, Tolmane I, Alzaabi M, Hajarizadeh B, Valantinas J, Kim DY, Hunyady B, Abaalkhail F, Abbas Z, Abdou A, Abourached A, Al Braiki F, Al Hosani F, Al Jaberi K, Al Khatry M, Al Mulla MA, Al Quraishi H, Al Rifai A, Al Serkal Y, Alam A, Alashgar HI, Alavian SM, Alawadhi S, Al-Dabal L, Aldins P, Alghamdi AS, Al-Hakeem R, Aljumah AA, Almessabi A, Alqutub AN, Alswat KA, Altraif I, Andrea N, Assiri AM, Babatin MA, Baqir A, Barakat MT, Bergmann OM, Bizri AR, Chaudhry A, Choi MS, Diab T, Djauzi S, El Hassan ES, El Khoury S, Estes C, Fakhry S, Farooqi JI, Fridjonsdottir H, Gani RA, Ghafoor Khan A, Gheorghe L, Goldis A, Gottfredsson M, Gregorcic S, Gunter J, Hamid S, Han KH, Hasan I, Hashim A, Horvath G, Husni R, Jafri W, Jeruma A, Jonasson JG, Karlsdottir B, Kim YS, Koutoubi Z, Lesmana LA, Liakina V, Lim YS, Löve A, Maimets M, Makara M, Malekzadeh R, Memon MS, Merat S, Mokhbat JE, Mourad FH, Muljono DH, Nawaz A, Olafsson S, Priohutomo S, Qureshi H, Rassam P, Razavi H, Razavi-Shearer D, Razavi-Shearer K, Rozentale B, Sadik M, Saeed K, Salamat A, Salupere R, Sanai FM, Sanityoso Sulaiman A, Sayegh RA, Schmelzer JD, Sharara AI, Sibley A, Siddiq M, Siddiqui AM, Sigmundsdottir G, Sigurdardottir B, Speiciene D, Sulaiman A, Sultan MA, Taha M, Tanaka J, Tarifi H, Tayyab G, Ud Din M, Umar M, Videčnik-Zorman J, Yaghi C, Yunihastuti E, Yusuf MA, Zuberi BF, Blach S.

J Viral Hepat. 2015 Dec;22 Suppl 4:42-65. doi: 10.1111/jvh.12474.

PMID:
26513447

Supplemental Content

Loading ...
Support Center